Durable Intracranial Response to Sacituzumab Tirumotecan in HER2 ‐Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report
Cancer Reports · 2026
DOI: 10.1002/cnr2.70676 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Guang-Liang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Salivary Gland Neoplasms, Cell Adhesion Molecules, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Salivary duct carcinoma is an aggressive salivary gland malignancy in which systemic therapy is often guided by androgen receptor and HER2 status. Treatment options are limited for HER2‐negative disease after progression on androgen‐deprivation therapy and chemotherapy, particularly when active central nervous system (CNS) involvement develops. Case A 62‐year‐old man with androgen receptor‐positive, HER2‐negative salivary duct carcinoma developed progressive intracranial dural metastases involving the left temporal and occipital regions after surgery, adjuvant radiotherapy, androgen‐deprivation therapy, and multiple chemotherapy‐based regimens. The dominant lesion was a 33.6‐mm left temporal dural‐based mass extending across the left tentorial leaflet. Immunohistochemical profiling of archival primary tumor tissue showed high membranous TROP2 expression (H‐score, 230). Off‐label sacituzumab tirumotecan was initiated at 350 mg every 2 weeks without concurrent corticosteroids or local CNS‐directed therapy. Serial magnetic resonance imaging demonstrated sustained regression of the dominant left temporal mass from 33.6 to 15.3 mm (−54.5%), with no new intracranial lesions. Intracranial disease control was maintained for approximately 9 months. Treatment‐related Grade 2 oral mucositis and leukopenia improved with supportive care and did not require dose reduction or treatment discontinuation.
Conclusion
In heavily pretreated, HER2‐negative salivary duct carcinoma with high TROP2 expression and progressive intracranial dural metastases, sacituzumab tirumotecan was associated with a durable intracranial response without local CNS‐directed therapy. This observation supports further clinical evaluation of TROP2‐directed antibody–drug conjugates in salivary duct carcinoma with CNS involvement, while the predictive value of TROP2 expression remains to be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Medical Oncology, Lichuan Ethnic Hospital of Traditional Chinese Medicine, Lichuan, Hubei, China.
- Department of Nursing, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Guang-Liang Chen, Xin Liu, Dongmei Ji
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, G. L., Tan, B., Cao, S., Liu, X., Guo, Y., & Ji, D. (2026). Durable Intracranial Response to Sacituzumab Tirumotecan in HER2 ‐Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70676
Vancouver
Chen GL, Tan B, Cao S, Liu X, Guo Y, Ji D. Durable Intracranial Response to Sacituzumab Tirumotecan in HER2 ‐Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report. Cancer Reports. 2026. doi:10.1002/cnr2.70676
BibTeX
@article{Chen2026,
author = {Chen, Guang-Liang and Tan, Biao and Cao, Sufen and Liu, Xin and Guo, Yanjing and Ji, Dongmei},
title = {Durable Intracranial Response to Sacituzumab Tirumotecan in HER2 ‐Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70676}
}
EUVIMED